Novel Targets for Anticancer Treatment Development in Colorectal Cancer
- 1 November 2006
- journal article
- review article
- Published by Elsevier in Clinical Colorectal Cancer
- Vol. 6 (4), 265-272
- https://doi.org/10.3816/ccc.2006.n.045
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- A Fully Human Recombinant IgG-like Bispecific Antibody to Both the Epidermal Growth Factor Receptor and the Insulin-like Growth Factor Receptor for Enhanced Antitumor ActivityJournal of Biological Chemistry, 2005
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2004
- Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancerNature Reviews Drug Discovery, 2004
- In vivo antitumor activity of NVP-AEW541—A novel, potent, and selective inhibitor of the IGF-IR kinaseCancer Cell, 2004
- Overexpression of the insulin‐like growth factor I receptor in human colon carcinomasCancer, 2002
- The growth hormone–insulin-like growth factor-I axis and colorectal cancerTrends in Molecular Medicine, 2001
- Role of the Insulin-Like Growth Factor Family in Cancer Development and ProgressionJNCI Journal of the National Cancer Institute, 2000
- Expression of insulin-like growth factor-1 receptor in human colorectal cancerHuman Pathology, 1999
- Prospective Study of Colorectal Cancer Risk in Men and Plasma Levels of Insulin-Like Growth Factor (IGF)-I and IGF-Binding Protein-3JNCI Journal of the National Cancer Institute, 1999
- Mammary cancer in transgenic mice expressing insulin-like growth factor II (IGF-II)British Journal of Cancer, 1995